It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Laboratory Corporation of America Holdings (LH) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $3.01, or 1.37%, to $222.23. The Laboratory Corporation of America Holdings has recorded 60,900 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Ovia HealthTM Expands Digital Platform Capabilities to Include Menopause Tracking.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Laboratory Corporation of America Holdings is listed on the NYSE in the Healthcare sector while operating in the Diagnostics & Research industry. At the end of the last regular session, the stock closed at $219.22 and fluctuated between $220.33 as its day high and $216.34 as its day low. The current market capitalization of Laboratory Corporation of America Holdings is $19.54B. A total of 0.66 million shares were traded on the day, compared to an average of 635.12K shares.
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, LH has seen 21 BUY and 24 SELL insider trades, representing the acquisition of 16,488 and the disposition of 13,198 shares. Over the last 12 months, there were 41 BUYs and 51 SELLs from insiders. Insiders purchased 108,866 shares during that period but sold 105,080.
In the most recent transaction, Kirchgraber Paul R sold 8,000 shares of LH for 250.58 per share on Feb 21. After the transaction, the CEO, Covance Drug Development now owns 9,069 company shares. In a previous transaction on Feb 14, Schroeder Mark S sold 309 shares at 247.63 per share. LH shares that EVP, President-Diagnostics Lab owns now total 6,687.
Among the insiders who sold shares, Schroeder Mark S disposed of 409 shares on Feb 07 at a per-share price of $243.01. This resulted in the EVP, President-Diagnostics Lab holding 6,687 shares of LH after the transaction. In another insider transaction, van der Vaart Sandra D sold 219 shares at $243.01 per share on Feb 07. Company shares held by the EVP, Chief Legal Officer now total 5,341.
The reasons why investors prefer dividend-paying companies are that dividends generate immediate cash flow and indicate that the company will perform well in the future. Laboratory Corporation of America Holdings pays an annual dividend of $2.88, resulting in a dividend yield of 1.31%, and it has a price to earnings (P/E) ratio of 15.84. LH’s most recent ex-dividend date was 2/22/2023 when it declared a $0.72 quarterly dividend that was paid in cash on 3/13/2023. Previously, the company paid the dividend on 12/9/2022 with an ex-dividend date of 11/16/2022. The LH stock dividend was $0.72 per share in cash.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for LH in the last 3 months, the mean price target is $285.77 with high estimates of $300.00 and low estimates of $260.00. In terms of 52-week highs and lows, LH has a high of $281.22 and a low of $200.32.
As of this writing, LH has an earnings estimate of $4.11 per share for the current quarter. EPS was calculated based on a consensus of 13 estimates, with a high estimate of $4.43 per share and a lower estimate of $3.95. The company reported an EPS of $4.95 in the last quarter, which was 5.30% higher than expectations of $4.7.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 15 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for LH is Underweight with a score of 4.42. A total of 11 analysts rated the stock as Buy while 1 rated it as Overweight while 3 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.